Anti-CD20 Antibodies and CARs for B-Cell Lymphoma Targeting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for adult B-cell malignancies, such as acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, and non-Hodgkin's lymphoma, are incurable, and the hostile tumor microenvironment hampers the effectiveness of immunotherapy approaches like adoptive cell transfer (ACT) by creating an immunosuppressive environment that protects malignant cells from immune recognition and elimination.

Innovation Solution

Development of anti-CD20 antibodies and CD20 antigen binding fragments, including chimeric antigen receptors (CARs), specifically designed for canine CD20, which enhance the targeting and elimination of B-cell malignancies by binding with high affinity to the CD20 antigen, and can be used in conjunction with immune cells like T-cells and NK cells to overcome the immunosuppressive microenvironment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If adoptive cell transfer (ACT) is used to treat B-cell malignancies, then immune response against tumor cells is enhanced, but the immunosuppressive tumor microenvironment blocks immune cell functionality and reduces treatment efficacy

Engineering Contradiction:

Improvetreatment efficacyVSAvoidimmunosuppressive microenvironment

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces anti-CD20 antibodies as intermediary molecules that mediate the interaction between immune cells (T cells, NK cells) and B-cell malignancies. These antibodies bind to CD20 on tumor cells and engage immune cells through Fc receptors, bridging the gap created by the immunosuppressive microenvironment and enabling effective tumor cell recognition and elimination.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs composite therapeutic approaches combining multiple mechanisms: adoptive cell transfer (ACT) with genetically engineered T cells expressing CARs or TCRs, combined with anti-CD20 antibody therapy. This composite strategy integrates cellular immunity with antibody-mediated immunity, creating a synergistic effect that overcomes the limitations of single-modality treatments in the face of immunosuppressive microenvironments.

Inventive Principle:

Principle #40Composite materials

2Ease of manufacture

If conventional therapies are used for adult B-cell malignancies, then treatment is administered, but the malignancies remain incurable

Engineering Contradiction:

Improvetreatment availabilityVSAvoidcure rate

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent fundamentally changes the therapeutic parameters by shifting from conventional chemotherapy to immunotherapy approaches. This includes using genetically engineered T cells with modified receptor specificity (CARs or TCRs) and anti-CD20 antibodies, representing a paradigm shift in treatment modality that transforms incurable malignancies into potentially curable conditions through enhanced immune recognition and elimination of B-cell cancers.

Inventive Principle:

Principle #35Parameter changes

3Measurement precision

If anti-CD20 antibodies are designed for high affinity binding to canine CD20, then targeting specificity is improved, but the complexity of antibody development and production increases

Engineering Contradiction:

Improvebinding specificityVSAvoidantibody development complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent performs preliminary actions in the antibody development process by pre-identifying and characterizing the canine CD20 antigen structure and epitopes before antibody generation. This includes selecting specific CD20 epitopes for immunization and pre-screening antibody candidates for optimal binding affinity and specificity, thereby streamlining the overall development process and reducing subsequent complexity while ensuring high binding precision.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The anti-CD20 antibodies and CARs effectively target and kill B-cell lymphoma cells, demonstrating improved efficacy in treating B-cell malignancies and autoimmune diseases by enhancing immune cell functionality and overcoming the immunosuppressive tumor microenvironment.

Implementation Method 1

the anti-CD20 antibodies and CD20 antigen binding fragments... bind with high affinity to the CD20 antigen

Methodology Applied

Scientific EffectAntigen-antibody binding:

Implementation Method 2

chimeric antigen receptors (CARs), specifically designed for canine CD20, which enhance the targeting and elimination of B-cell malignancies by binding with high affinity to the CD20 antigen

Methodology Applied

Scientific EffectChimeric antigen receptor binding:

Data Source

PatentUS12522664B2Anti-CD20 antibody and uses thereof

Publication Date: 2026.01.13 MEMORIAL SLOAN KETTERING CANCER CENT

AI summary

Provided herein are anti-CD20 antibodies and uses thereof for treatment and diagnosis. Also provided are CD20 antigens for the production of anti-CD20 antibodies and methods of generating anti-CD20 antibodies using the CD20 antigens.